title: Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine.
abstract: During the past 30 years, Romania reported rates of vaccine-associated paralytic poliomyelitis (VAPP) approximately 10-fold higher than in the United States. The elevated VAPP risk was largely caused by multiple intramuscular (im) injections with antibiotics given within 30 days of onset of paralysis. Because it is not known whether im injections contribute to the VAPP risk in the United States, we examined VAPP cases reported since 1980. We reviewed injection histories of VAPP cases reported to the Centers for Disease Control and Prevention from 1980 to 1993: with vaccines for 1980 to 1987; and for all substances for 1988 to 1993. Rates of VAPP by number of im injections with vaccines were calculated from 1988 to 1993 with estimated vaccine coverage data from the National Health Interview Survey. From 1980 to 1993 a total of 119 cases of poliomyelitis were reported to the Centers for Disease Control and Prevention. Of these, 87 (73%) were vaccine-associated and immunologically normal: 41 were oral polio vaccine (OPV) recipient cases; 40 were OPV contact cases; and 6 were community-acquired cases. A history of im injections in the 45 days before onset of paralysis was obtained from 28 (72%) of 39 recipient cases reported from 1980 to 1993 for which dates of paralysis onset could be determined and from 1 (8%) of 13 contact cases reported from 1988 to 1993. With one exception all substances administered intramuscularly were routine childhood vaccines. No clustering of im injections in the "high risk" windows, 0 to 3 and 8 to 21 days before onset of paralysis, was observed.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Epidemiology and Surveillance Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
authors.forename: H S
authors.initials: HS
authors.lastname: Izurieta
authors.forename: R W
authors.initials: RW
authors.lastname: Sutter
authors.forename: A L
authors.initials: AL
authors.lastname: Baughman
authors.forename: P M
authors.initials: PM
authors.lastname: Strebel
authors.forename: J M
authors.initials: JM
authors.lastname: Stevenson
authors.forename: M
authors.initials: M
authors.lastname: Wharton
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015994:Incidence; D007273:Injections, Intramuscular / Q000009:adverse effects*; D011051:Poliomyelitis / Q000453:epidemiology / Q000209:etiology*; D011055:Poliovirus Vaccine, Oral / Q000009:adverse effects*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D011055:Poliovirus Vaccine, Oral